Get started
Novo Nordisk A/SNovo Nordisk A/SNovo Nordisk A/S

Novo Nordisk A/S

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsOptionsBondsETFs
Full chart
Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪207.16 B‬ USD
Dividend yield (indicated)
2.81%
Price to earnings Ratio (TTM)
11.05
Basic EPS (TTM)
4.27 USD
Net income (FY)
‪15.49 B‬ USD
Revenue (FY)
‪46.74 B‬ USD
Shares float
‪3.37 B‬
Beta (1Y)
1.38

About Novo Nordisk A/S Class B


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Maziar Mike Doustdar
Website
novonordisk.com
Headquarters
Bagsværd
Founded
1923
IPO date
May 17, 1974
Identifiers
3
ISIN US6701002056
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


5.566% YTM
Maturity date May 21, 2026
Coupon 3.38% (Fixed)
4.424% YTM
Maturity date Nov 20, 2045
Coupon 4.00% (Fixed)
4.014% YTM
Maturity date Feb 20, 2038
Coupon 3.63% (Fixed)
3.960% YTM
Maturity date May 27, 2037
Coupon 3.63% (Fixed)
3.732% YTM
Maturity date Feb 20, 2035
Coupon 3.38% (Fixed)
3.655% YTM
Maturity date May 21, 2034
Coupon 3.38% (Fixed)
3.566% YTM
Maturity date May 27, 2033
Coupon 3.13% (Fixed)
3.466% YTM
Maturity date Feb 20, 2032
Coupon 3.00% (Fixed)
3.308% YTM
Maturity date Jan 21, 2031
Coupon 3.25% (Fixed)
3.304% YTM
Maturity date Aug 27, 2030
Coupon 2.88% (Fixed)
3.098% YTM
Maturity date Feb 20, 2029
Coupon 2.50% (Fixed)

See all NVO bonds 

ETFs holding the stock


PVAL
Putnam Focused Large Cap Value ETF
Weight 0.79%
Market value ‪79.17 M‬
PPH
VanEck Pharmaceutical ETF
Weight 6.12%
Market value ‪56.13 M‬
AVDE
Avantis International Equity ETF
Weight 0.30%
Market value ‪49.51 M‬
PID
Invesco International Dividend Achievers ETF
Weight 3.46%
Market value ‪31.96 M‬
WCMI
First Trust WCM International Equity ETF
Weight 1.83%
Market value ‪25.82 M‬
PINK
Simplify Health Care ETF
Weight 6.81%
Market value ‪17.57 M‬
LIFE.B
Evolve Global Healthcare Enhanced Yield Fund
Weight 6.43%
Market value ‪14.20 M‬
LIFE.U
Evolve Global Healthcare Enhanced Yield Fund Trust Units USD Unhedged
Weight 6.43%
Market value ‪14.20 M‬
LIFE
Evolve Global Healthcare Enhanced Yield Fund
Weight 6.43%
Market value ‪14.20 M‬
AQEC
AQE Core ETF
Weight 1.61%
Market value ‪9.16 M‬
476690
MIRAE ASSET TIGER GLOBAL OBESITY TREATMENT TOP 2 PLUS INDXX ETF Units
Weight 29.39%
Market value ‪8.62 M‬

Explore more ETFs